IL243941B - Polyconjugates for transporting rnai factors to cancer cells in vivo - Google Patents

Polyconjugates for transporting rnai factors to cancer cells in vivo

Info

Publication number
IL243941B
IL243941B IL243941A IL24394116A IL243941B IL 243941 B IL243941 B IL 243941B IL 243941 A IL243941 A IL 243941A IL 24394116 A IL24394116 A IL 24394116A IL 243941 B IL243941 B IL 243941B
Authority
IL
Israel
Prior art keywords
polyconjugates
vivo
delivery
tumor cells
rnai triggers
Prior art date
Application number
IL243941A
Other languages
English (en)
Hebrew (he)
Other versions
IL243941A0 (en
Original Assignee
Arrowhead Res Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arrowhead Res Corporation filed Critical Arrowhead Res Corporation
Publication of IL243941A0 publication Critical patent/IL243941A0/en
Publication of IL243941B publication Critical patent/IL243941B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06156—Dipeptides with the first amino acid being heterocyclic and Trp-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C07K5/0817—Tripeptides with the first amino acid being basic the first amino acid being Arg
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3535—Nitrogen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
IL243941A 2013-08-07 2016-02-03 Polyconjugates for transporting rnai factors to cancer cells in vivo IL243941B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361863056P 2013-08-07 2013-08-07
US14/452,626 US9487556B2 (en) 2013-08-07 2014-08-06 Polyconjugates for delivery of RNAi triggers to tumor cells in vivo
PCT/US2014/049851 WO2015021092A1 (en) 2013-08-07 2014-08-06 Polyconjugates for delivery of rnai triggers to tumor cells in vivo

Publications (2)

Publication Number Publication Date
IL243941A0 IL243941A0 (en) 2016-04-21
IL243941B true IL243941B (en) 2019-06-30

Family

ID=52449177

Family Applications (1)

Application Number Title Priority Date Filing Date
IL243941A IL243941B (en) 2013-08-07 2016-02-03 Polyconjugates for transporting rnai factors to cancer cells in vivo

Country Status (13)

Country Link
US (3) US9487556B2 (enExample)
EP (1) EP3030244B1 (enExample)
JP (1) JP6433001B2 (enExample)
KR (1) KR20160035081A (enExample)
CN (1) CN105451743B (enExample)
AU (1) AU2014306021B2 (enExample)
CA (1) CA2919088A1 (enExample)
EA (1) EA201690051A1 (enExample)
IL (1) IL243941B (enExample)
MX (1) MX2016001006A (enExample)
SG (1) SG11201600379TA (enExample)
TW (1) TWI685347B (enExample)
WO (1) WO2015021092A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105451743B (zh) * 2013-08-07 2019-11-19 箭头研究公司 用于在活体中递送RNAi触发子至肿瘤细胞的聚偶联物
EP3271482A4 (en) * 2015-03-17 2019-02-13 Arrowhead Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR INHIBITING THE GENE EXPRESSION OF FACTOR XII
WO2016149313A1 (en) * 2015-03-17 2016-09-22 Arrowhead Research Corporation Improved disulfide-containing alkyne linking agents
KR102633963B1 (ko) 2015-05-29 2024-02-05 애로우헤드 파마슈티컬스 인코포레이티드 생물학적으로 절단가능한 테트라펩티드 연결제
JP7021076B2 (ja) 2015-05-29 2022-02-16 アローヘッド ファーマシューティカルズ インコーポレイテッド Ｈｉｆ２αの遺伝子発現を阻害する組成物及び方法
EP3252082A1 (en) * 2016-05-31 2017-12-06 Galderma S.A. Method for deacetylation of biopolymers
ES2962687T3 (es) * 2015-12-29 2024-03-20 Galderma Holding SA Reticulación de carbohidratos
PT3623390T (pt) * 2016-05-31 2023-10-27 Galderma Sa Reticulador de hidrato de carbono
EP3630189A4 (en) 2017-05-24 2021-06-23 The Board of Regents of The University of Texas System Linkers for antibody drug conjugates
SG11202009734VA (en) 2018-04-27 2020-11-27 Arrowhead Pharmaceuticals Inc Integrin targeting ligands and uses thereof
KR20210113273A (ko) 2019-01-09 2021-09-15 애로우헤드 파마슈티컬스 인코포레이티드 HIF-2 알파 (EPAS1)의 발현을 억제하기 위한 RNAi 작용제, 그의 조성물, 및 사용 방법
CN110240551B (zh) * 2019-06-25 2022-02-11 成都郑源生化科技有限公司 Fmoc-β-Ala-Gly-OH的制备方法
WO2021111303A1 (en) 2019-12-02 2021-06-10 Galderma Holding SA High molecular weight esthetic compositions
CN113004515B (zh) * 2021-03-02 2023-02-24 厦门大学附属中山医院 一种仿透明质酸聚氨基酸衍生物、其制备方法及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT850221E (pt) * 1995-08-30 2001-11-30 Searle & Co Derivados de meta-guanidina ureia tioureia ou acido aminobenzoico azaciclico como antagonistas de integrina
AU2337097A (en) 1996-03-29 1997-10-22 G.D. Searle & Co. Meta-substituted phenylene derivatives and their use as alphavbeta3 integrin antagonists or inhibitors
EP0927045B1 (en) * 1996-09-10 2005-12-14 The Burnham Institute Tumor homing molecules, conjugates derived therefrom, and methods of using same
AU6067098A (en) 1997-04-07 1998-10-08 Cfpi Nufarm Preparation process for 3,4-disubstituted dinitroanilines
CA2464271A1 (en) * 2001-10-22 2003-05-01 The Scripps Research Institute Integrin targeting compounds
JP2004261024A (ja) * 2003-02-28 2004-09-24 Japan Science & Technology Agency ペプチド修飾多糖類を用いる遺伝子治療剤
CA2488224A1 (en) * 2003-04-03 2004-10-21 Alnylam Pharmaceuticals, Inc. Irna conjugates
EP1742958B1 (en) 2004-03-15 2017-05-17 City of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded rna
AU2005304816A1 (en) * 2004-11-04 2006-05-18 Raul Andino Syntheses of polyamine conjugates of small interfering RNAs (si-RNAs) and conjugates formed thereby
JP2008537752A (ja) * 2005-04-12 2008-09-25 イントラディグム コーポレイション がんおよび他の新血管形成疾患を処置するためのＲＮＡｉ治療用の組成物および方法
EP2061443A4 (en) * 2006-08-18 2013-07-24 Arrowhead Res Corp POLYCONJUGATE FOR IN VIVO ADMINISTRATION OF POLYNUCLEOTIDES
US8017109B2 (en) 2006-08-18 2011-09-13 Roche Madison Inc. Endosomolytic poly(acrylate) polymers
EP2076257A4 (en) * 2006-09-15 2014-04-16 Belrose Pharma Inc POLYMER CONJUGATES WITH POSITIVELY LOADED PARTS
WO2008045252A2 (en) 2006-10-04 2008-04-17 The Board Of Trustees Of The Leland Stanford Junior University Engineered integrin binding peptides
EP2379083B1 (en) 2008-12-18 2017-08-16 Dicerna Pharmaceuticals, Inc. Extended dicer substrate agents and methods for the specific inhibition of gene expression
US20100249214A1 (en) 2009-02-11 2010-09-30 Dicerna Pharmaceuticals Multiplex dicer substrate rna interference molecules having joining sequences
ES2562817T3 (es) 2010-02-24 2016-03-08 Arrowhead Research Corporation Composiciones para el suministro dirigido de ARNip
US8501930B2 (en) * 2010-12-17 2013-08-06 Arrowhead Madison Inc. Peptide-based in vivo siRNA delivery system
CA2816041C (en) * 2010-12-29 2019-01-08 Arrowhead Research Corporation In vivo polynucleotide delivery conjugates having enzyme sensitive linkages
KR20130108655A (ko) 2010-12-29 2013-10-04 에프. 호프만-라 로슈 아게 핵산의 세포내 전달을 위한 소분자 접합체
KR20140051357A (ko) 2011-08-26 2014-04-30 애로우헤드 리서치 코오포레이션 Ｉｎ Ｖｉｖｏ 핵산 전달용 폴리(비닐 에스테르) 고분자
EP2806899B1 (en) * 2012-01-27 2016-10-19 F.Hoffmann-La Roche Ag Integrin antagonist conjugates for targeted delivery to cells expressing alpha-v-beta-3
US20130197205A1 (en) 2012-01-27 2013-08-01 Hoffmann-La Roche Inc. Chitosan covalently linked with small molecule integrin antagonist for targeted delivery
JP2015515530A (ja) 2012-04-18 2015-05-28 アローヘッド リサーチ コーポレイション インビボ核酸送達のためのポリ（アクリラート）ポリマー
CN105451743B (zh) * 2013-08-07 2019-11-19 箭头研究公司 用于在活体中递送RNAi触发子至肿瘤细胞的聚偶联物

Also Published As

Publication number Publication date
EA201690051A1 (ru) 2016-06-30
IL243941A0 (en) 2016-04-21
CN105451743B (zh) 2019-11-19
TWI685347B (zh) 2020-02-21
US20170022497A1 (en) 2017-01-26
KR20160035081A (ko) 2016-03-30
JP6433001B2 (ja) 2018-12-05
US9487556B2 (en) 2016-11-08
SG11201600379TA (en) 2016-02-26
AU2014306021A2 (en) 2016-11-24
JP2016535058A (ja) 2016-11-10
EP3030244A4 (en) 2017-06-28
HK1220397A1 (zh) 2017-05-05
US20150045573A1 (en) 2015-02-12
EP3030244B1 (en) 2021-04-21
MX2016001006A (es) 2016-04-19
AU2014306021A1 (en) 2016-01-28
CN105451743A (zh) 2016-03-30
AU2014306021B2 (en) 2018-12-13
WO2015021092A1 (en) 2015-02-12
EP3030244A1 (en) 2016-06-15
US20190062748A1 (en) 2019-02-28
CA2919088A1 (en) 2015-02-12
TW201601742A (zh) 2016-01-16

Similar Documents

Publication Publication Date Title
IL243941B (en) Polyconjugates for transporting rnai factors to cancer cells in vivo
IL244113B (en) Selective delivery of substance to cells
ZA201507790B (en) Enhanced adoptive cell therapy
PT2768493T (pt) Fitocanabinoides para utilização no tratamento do cancro da mama
PL3234107T3 (pl) Limfocyty b do dostarczania in vivo środków terapeutycznych
EP2971040A4 (en) CELL CULTURE METHODS
EP2971014A4 (en) CELL CULTURE METHODS
EP2872036A4 (en) IN VIVO BIOSENSOR
ZA201406726B (en) Methods and composition related to brown adipose-like cells
PL2925223T3 (pl) Udoskonalone sposoby oceny funkcji metabolicznej
IL290429A (en) Improved methods for genetic modification in animal cells
SG10201800017RA (en) Cell preparation including fat cell
GB2510826B (en) Improvements in or relating to release of a beneficial substance from a bolus
ZA201408383B (en) Improved endoglucanases for treatment of cellulosic material
SG11201502214PA (en) Adipose tissue cells
GB201516123D0 (en) In vivo cell imaging
PL2950663T3 (pl) Sposoby podnoszenia jakości roślin na kiszonki
PL3082858T3 (pl) Środek wiążący adrenomedulinę do zastosowania w terapii nowotworu
GB201302197D0 (en) Method of increasing lipid accumulation in pulcherrima cells
GB201304514D0 (en) Cell delivery
EP2738248A4 (en) METHOD FOR THE PRODUCTION OF VITRO VASCULARIZED TISSUE
EP2720720A4 (en) PLURITHERAPY TO PREVENT DCIS FORMATION AND EVOLUTION IN BREAST CANCER
IL233166A0 (en) A programmable cell model for defining cancer treatments
GB201216936D0 (en) Adipose tissue cells
GB201216933D0 (en) Adipose tissue cells

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed